NASDAQ:GH 30 October 2025 - 20 June 2026

Guardant’s latest quarterly report blew past Wall Street’s expectations, sparking a sharp rally in its shares. For Q3 2025, revenue was $265.2 million, a 39% jump from a year ago and well above the ~$235 million analysts had forecastinvesting.com. On an adjusted basis, Guardant lost $0.39 per share, much better than the roughly $0.79 loss expected. Management immediately lifted the full-year sales outlook to $965–970 millioninvestors.guardanthealth.com, up from $915–925M previously. As a result, GH stock jumped nearly 30% in morning trading on Oct. 30seekingalpha.comreuters.com. This breakout comes on top of an already huge run – shares were up over 210% year-over-year before the earnings releaseinvesting.com. Guardant’s co-CEOs hailed the quarter’s breadth. Helmy Eltoukhy noted it was an “exceptional quarter” with “broad-based growth across our business,” including 40% year-over-year volume growth in cancer testinginvestors.guardanthealth.com. He pointed out that this strong momentum lifted Guardant past a $1 billion annualized revenue run-rate for the first time, underscoring the power of its liquid-biopsy and screening offerings. In short, real revenue growth is accelerating, giving investors confidence in Guardant’s path.